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should be compared with G-CSF mobilized peripheral blood stem
cell collection.
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NEUTROPENIA AND THROMBOCYTOPENIA INDUCED BY G-CSF ADMIN-
ISTRATION IN HEALTHY PBSC ALLOGENEIC DONORS: HOW LONG
SHOULD BE PROLONGED HEMATOLOGICAL AND CLINICAL SURVEIL-
LANCE?
Tassi, C., Anna, N., Valeria, G., Roberto, C. Medical Transfusion
Service-Sant’orsola, Bologna, Bologna, Italy
From February 1998, one hundred and twenty peripheral blood
stem cell (PBSC) healthy donors were treated with G-CSF for 4-7
days and submitted to leukoapheresis courses in the Apheresis Unit
of our Service. All were enrolled on short and long-term clinical
and hematological surveillance protocol for a ﬁve year time. To-
date, 95 donors are evaluable: overall mean follow-up time is 31
months, being 36 months in 45 and 12 months in 13 subjects.
Main clinical adverse effects to Lenograstim were headhache
(65%), musculo-skeletal pain (78%) and fatigue (69%); no therapy
or low paracetamol doses were employed in 95% of the donors.
Pre-leukoapheresis mean platelet reduction was assessed at 23.6%
 9% and detected in 42/95 cases; an additional decrease of
absolute WBC counts, in particular due to both PMN and Lym-
phocyte low numbers, was diagnosed in 27 subjects of this group.
Pre-G-CSF administration platelet values were observed at 12
months of follow-up. Multivariate and univariate analysis demon-
strated a correlation between duration of G-CSF administration
(p.004), pre G-CSF platelet level (p.003) and decreased platelet
count before leukoapheresis. At this regard, PMN and or lympho-
cyte lower values were counted in 75 out of 95 donors two weeks
after G-CSF administration, whereas PMN and Lymphocytes
were signiﬁcantly decreased in 43 out of the 75 subjects (-39.3%
and -30%, respectively). Transient PMN count below 1000/ul was
detected in 4/43 cases. Finally, in 12/43 donors pre mobilization
number of PMNs or Lymphocytes were reached only after 24
months of follow-up time. Univariate and multivariate analysis
demonstrated strict correlation between-n reduction at 4, 8,
and 12 months of follow-up, and G-CSF administration days
(p.0021)  pre-mobilization PMN absolute counts (p.003). Sex
and age of patients did not signiﬁcantly correlate with WBC
decremental trend; however, isolated PMN low values were more
frequently observed in young patients, since in this group mean age
was 38.5  15 yrs in comparison to lymphocytopenic donors
(44.7 5 yrs). Taken altogether, these results seem to demonstrate
in younger PBSC donors treated with G-CSF for more than ﬁve
days, negative effects on myelopoiesis lasting two years, without
any ﬁndings of haematological disorders or clinical sign of disease.
In these limited cases, a hematocromocytometric observation may
be prudentially prolonged over ﬁve years.
AUTOLOGOUS
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PEGFILGRASTIM (NEULASTA) FOLLOWING CHEMOTHERAPY LEADS
TO SUCCESSFUL MOBILIZATION OF HEMATOPOIETIC PROGENITOR
CELLS AMONG TRANSPLANT PATIENTS WITH VARIOUS DIAGNOSES
Mandanas, R.A.1, Underwood, B.J.1, Geister, B.V.1, Smith, J.W.2 1.
Western Oklahoma Blood and Marrow Transplant Program, Cancer
Care Associates, Oklahoma City, OK;2. Oklahoma Blood Institute, Okla-
homa City, OK
Filgrastim has been traditionally used following chemotherapy to
mobilize hematopoietic progenitor cells. Doses of 5-10 g/kg/day
subcutaneously have been given until recovery of WBC counts to
over 5.0  103/L before initiating leukapheresis. Pegﬁlgrastim
(Neulasta™) produced by covalently binding a 20-kd monome-
thoxypolyethylene glycol molecule to the N-terminal methionyl
residue of ﬁlgrastim has a much longer half-life allowing for a
single 6 mg subcutaneous injection with similar efﬁcacy and safety
proﬁle as ﬁlgrastim in reducing the duration of severe chemother-
apy-induced neutropenia. Thirteen patients with various diagnoses
(6 Myeloma, 4 NHL, 1 breast cancer, 1 seminoma, 1 CLL) re-
ceived pegﬁlgrastim 6 mg single injection 1 day after completing
mobilization chemotherapy (cytoxanetoposide  8; cytoxan  2;
ICE  Rituximab  2; taxotereadriamycincytoxan  1). The
median age was 56 years (28-71) with 8 females and 5 males.
Leukapheresis processing 3 times the estimated blood volume was
initiated beginning recovery of total WBC count to at least 5.0 
103/L. The minimum target of 2.5  106/kg CD34 cell count
was achieved 100% in all 13 patients after only one day of leuka-
pheresis. The optimal target of 5.0  106/kg CD 34 cell count
was obtained in 85% (11/13 patients) in a single day of collection.
The mean CD34 cell count collected in the ﬁrst day was 16.8 
106/kg (median 13.6, range 2.5 – 45.5). Two patients (1 CLL, 1
Myeloma with CLL) had their harvested product CD34-selected
before cryopreservation. All patients engrafted following their au-
totransplants. Engraftment data were as predicted for peripheral
blood stem cell recovery times (Time to ANC of 500/L: mean
10.3 days, range 8-11 and time to Platelet count 20  103/L:
mean 11.5 days, range 9-15). In conclusion, pegﬁlgrastim given as
a single 6 mg subcutaneous injection after chemotherapy is a viable
alternative to multiple daily injections of ﬁlgrastim for the mobi-
lization of hematopoiteic progenitor cells.
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PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN A LARGE
SERIES OF PATIENTS WITH POEMS SYNDROME
Dispenzieri, A.1, Moreno-Aspitia, A.2, Lacy, M.Q.1, Colon-Otero, G.2,
Tefferi, A.1, Litzow, M.R.1, Gertz, M.A.2 1. Mayo Clinic, Rochester,
MN; 2. Mayo Clinic, Jacksonville, FL
Background: The POEMS syndrome is characterized by pe-
ripheral neuropathy (PN), clonal plasma cell disorder (PCD), or-
ganomegaly, endocrinopathy, skin changes, edema, sclerotic bone
lesions, and thrombocytosis. Based on the improved response rates
observed with PBSCT in patients with other PCD, autologous
Table. Summary of Serious Marrow Complications
3
Symptom
Nature/
Duration
2Proximal
Cause
Acute/
Atypical
Acute/
Known Cancer
Herniated
Disk
Prolonged
Recovery/
Mild
Prolonged
Recovery/
Moderate-
Severe Total
Anesthesia 15
(75%)
28
(97%)
0 0 2
(7%)
0 45
(36%)
Infection 1 (5%) 0 0 0 0 0 1
(1%)
Mechanical
Injury
4 (20%) 0 0 0 25
(93%)
40
(100%)
69
(55%)
Unrelated/
Other
0 1
(3%)
6
(100%)
3
(100%)
0 0 10
(8%)
Total 20 29 6 3 27 40 125
Table. Variation of PMN in 24 Months of Follow-up Time
T0 PMN
counts
%
Decre-
ment
 14
%
Decre-
ment
 4m
%
Decre-
ment
 8m
%
Decre-
ment
 12m
%
Decre-
ment
 24m
10 Patients
lymphopenic 3310  320
not
change
not
change
not
change
not
change
not
change
22 Patients
neutropenic 4450  1220 37.5  13.9 12  5 8  3 9  3.5 12.4  4
43 Patients ly
 neutro-
penic  3855  456 39.5  14 15  3.7 10  2.8 13  6 21.6  9
Oral Presentations
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